Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma, Inc. reports biopharmaceutical developments centered on YUPELRI® (revefenacin) inhalation solution, an FDA-approved maintenance treatment for chronic obstructive pulmonary disease. Company updates commonly address YUPELRI collaboration revenue, U.S. net sales recognized by Viatris, hospital-channel demand, brand profitability, and intellectual-property matters related to generic challenges.
Theravance news also covers portfolio changes following the Phase 3 CYPRESS study of ampreloxetine in symptomatic neurogenic orthostatic hypotension due to multiple system atrophy, including the decision to wind down that program. Recurring corporate updates include cost-reduction actions, operating expense trends, TRELEGY milestone economics reported by GSK, cash position, and governance or capital-allocation reviews.
Theravance Biopharma (NASDAQ: TBPH) reported Q1 2026 results and a corporate update on May 7, 2026. Total revenue was $17.7 million, driven by a 15% increase in Viatris collaboration revenue. Quarter-end cash was $394.7 million with no debt. Q1 net loss was $4.9 million; non-GAAP net income from operations was $0.6 million. YUPELRI collaboration revenue rose on higher net sales and operating leverage; Viatris-reported Q1 U.S. YUPELRI net sales were $62.4 million (+7% YoY). TRELEGY global net sales were $873 million (+2% YoY) and the company expects a potential $100 million 2026 milestone. The Board's Strategic Review Committee is evaluating strategic alternatives. The company is executing a restructuring to reduce operating expenses ~60% and wind down R&D.
Theravance Biopharma (NASDAQ: TBPH) reported Q4 and full-year 2025 results and a corporate update on March 19, 2026. Key points: YUPELRI FY net sales $266.6M (+12% YoY) triggered a $25M milestone; TRELEGY FY net sales ~$3.9B (+13% YoY) triggered $50M. Company ended Q4 with $326.5M cash and expects ~ $400M at 3/31/2026; no debt. Following Phase 3 CYPRESS results, Theravance is winding down R&D, cutting operating expenses ~60% and targeting $60–$70M of annualized cash flow starting Q3 2026. A Board Strategic Review Committee is accelerating evaluation of value-maximizing alternatives, including a possible sale.
Theravance Biopharma (NASDAQ: TBPH) reported that the Phase 3 CYPRESS study of ampreloxetine did not meet the primary OHSA composite endpoint, and the company will wind down the program. The Board's Strategic Review Committee is accelerating a review of alternatives, including a potential sale. The company is restructuring to cut operating expenses ~60% (≈$70M run-rate), expect ~50% workforce reduction, and forecasts $60–$70M annualized cash flow starting Q3 2026. Cash was $326.5M at 12/31/2025; approximately $400M expected EoQ1 2026, and a $100M TRELEGY milestone is expected in 2026.
Theravance Biopharma (NASDAQ: TBPH) will host a virtual key opinion leader investor event on December 8, 2025 at 10:30 AM ET to review ampreloxetine's Phase 3 clinical development program for symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) ahead of topline data expected in Q1 2026. The session will feature Horacio Kaufmann, MD, and company management discussing the unmet medical need in MSA, the CYPRESS Phase 3 study design informed by positive REDWOOD results, and ampreloxetine's commercial opportunity and strategy. A live Q&A will follow.
Theravance Biopharma (NASDAQ: TBPH) will host a virtual key opinion leader investor event on December 8, 2025 at 10:30 AM ET to review ampreloxetine's Phase 3 clinical development program for symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) ahead of topline data expected in Q1 2026. The session will feature Horacio Kaufmann, MD, and company management discussing the unmet medical need in MSA, the CYPRESS Phase 3 study design informed by positive REDWOOD results, and ampreloxetine's commercial opportunity and strategy. A live Q&A will follow.
Theravance Biopharma (NASDAQ: TBPH) said management will participate in two investor conferences in December 2025: a Fireside Chat at the Evercore Healthcare Conference on Dec 4, 2025, 8:20–8:40 AM ET in Coral Gables, FL (live webcast), and a Panel at the Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025, 2:15–2:45 PM ET in New York. Theravance will be available for one-on-one meetings at both events. Interested investors should contact their representatives to request meetings. The Evercore webcast will be accessible on the company Events and Presentation investor page with a replay archived for 30 days.
Theravance Biopharma (NASDAQ: TBPH) said management will participate in two investor conferences in December 2025: a Fireside Chat at the Evercore Healthcare Conference on Dec 4, 2025, 8:20–8:40 AM ET in Coral Gables, FL (live webcast), and a Panel at the Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025, 2:15–2:45 PM ET in New York. Theravance will be available for one-on-one meetings at both events. Interested investors should contact their representatives to request meetings. The Evercore webcast will be accessible on the company Events and Presentation investor page with a replay archived for 30 days.
Theravance Biopharma (NASDAQ: TBPH) reported Q3 2025 results on Nov 10, 2025: YUPELRI U.S. net sales hit a record $71.4M (+15% YoY) and brand profitability improved. The company achieved non-GAAP breakeven in Q3 and ended September 30 with $332.7M cash and no debt. Enrollment in the pivotal Phase 3 CYPRESS trial of ampreloxetine is complete; the open-label portion finished and topline readout is expected in Q1 2026, with plans to prepare an expedited NDA and request priority review if supportive. TRELEGY global sales trends are on track to trigger milestone payments from Royalty Pharma if required sales levels are met in Q4 2025. A virtual KOL investor event on ampreloxetine is scheduled for Dec 8, 2025.
Theravance Biopharma (NASDAQ: TBPH) reported Q3 2025 results on Nov 10, 2025: YUPELRI U.S. net sales hit a record $71.4M (+15% YoY) and brand profitability improved. The company achieved non-GAAP breakeven in Q3 and ended September 30 with $332.7M cash and no debt. Enrollment in the pivotal Phase 3 CYPRESS trial of ampreloxetine is complete; the open-label portion finished and topline readout is expected in Q1 2026, with plans to prepare an expedited NDA and request priority review if supportive. TRELEGY global sales trends are on track to trigger milestone payments from Royalty Pharma if required sales levels are met in Q4 2025. A virtual KOL investor event on ampreloxetine is scheduled for Dec 8, 2025.
Theravance Biopharma (NASDAQ: TBPH) will present four ampreloxetine presentations at the 36th International Symposium on the Autonomic Nervous System, Nov 5-8, 2025, in Clearwater Beach, FL.
One platform presentation on precision therapy in multiple system atrophy (MSA) will be given on Nov 8, 2025 at 8:30 am ET. Three posters on supine hypertension, retention strategies, and enrollment strategies will be presented on Nov 6, 2025 at 7:00-8:30 pm ET. Topline results from the ongoing Phase 3 CYPRESS study are anticipated in Q1 2026.